Search

Author/Creator Dummer, Reinhard

31. Author Correction: High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. (November 2018)

Authors:
Krieg, Carsten; Nowicka, Malgorzata; Guglietta, Silvia; Schindler, Sabrina; Hartmann, Felix; Weber, Lukas; Dummer, Reinhard; Robinson, Mark; Levesque, Mitchell; Becher, Burkhard
Journal:
Nature medicine
Issue:
Volume 24:Number 11(2018)
Page Start:
1773
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

34. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Issue 4 (April 2017)

Authors:
Dummer, Reinhard; Schadendorf, Dirk; Ascierto, Paolo A; Arance, Ana; Dutriaux, Caroline; Di Giacomo, Anna Maria; Rutkowski, Piotr; Del Vecchio, Michele; Gutzmer, Ralf; Mandala, Mario; Thomas, Luc; Demidov, Lev; Garbe, Claus; Hogg, David; Liszkay, Gabriella; Queirolo, Paola; Wasserman, Ernesto; Fo...
Journal:
Lancet oncology
Issue:
Volume 18:Issue 4(2017:Apr.)
Page Start:
435
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

35. Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation. (1st January 2020)

Authors:
Saulite, Ieva; Ignatova, Desislava; Chang, Yun-Tsan; Fassnacht, Christina; Dimitriou, Florentia; Varypataki, Eleni; Anzengruber, Florian; Nägeli, Mirjam; Cozzio, Antonio; Dummer, Reinhard; Scarisbrick, Julia; Pascolo, Steve; Hoetzenecker, Wolfram; Bobrowicz, Malgorzata; Guenova, Emmanuella
Journal:
Oncoimmunology
Issue:
Volume 9:Number 1(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

36. Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer. Issue 2 (22nd December 2020)

Authors:
Hurkmans, Daan P; Verdegaal, Els M E; Hogan, Sabrina A; de Wijn, Rik; Hovestad, Lies; van den Heuvel, Dianne M A; Ruijtenbeek, Rob; Welters, Marij J P; van Brakel, Mandy; Basak, Edwin A; Pinedo, Herbert M; Lamers, Cor H J; van de Werken, Harmen J G; Groten, John P; Debets, Reno; Levesque, Mitchel...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8:Issue 2(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

37. Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer. Issue 2 (22nd December 2020)

Authors:
Hurkmans, Daan P; Verdegaal, Els M E; Hogan, Sabrina A; de Wijn, Rik; Hovestad, Lies; van den Heuvel, Dianne M A; Ruijtenbeek, Rob; Welters, Marij J P; van Brakel, Mandy; Basak, Edwin A; Pinedo, Herbert M; Lamers, Cor H J; van de Werken, Harmen J G; Groten, John P; Debets, Reno; Levesque, Mitchel...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8:Issue 2(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

38. Brentuximab vedotin (BV) versus physician's choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): final time to next therapy (TTNT) results from the phase 3 ALCANZA study. (2019)

Authors:
Scarisbrick, Julia; Horwitz, Steven M.; Prince, H. Miles; Whittaker, Sean; Duvic, Madeleine; Kim, Youn H.; Quaglino, Pietro; Zinzani, Pier Luigi; Bechter, Oliver; Eradat, Herbert; Pinter-Brown, Lauren; Akilov, Oleg; Geskin, Larisa; Sanches, Jose; Ortiz-Romero, Pablo; Lisano, Julie; Brown, Lisa; B...
Journal:
European journal of cancer
Issue:
Volume 119(2019)Supplement 1
Page Start:
S31
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

39. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Issue 10094 (5th August 2017)

Authors:
Prince, H Miles; Kim, Youn H; Horwitz, Steven M; Dummer, Reinhard; Scarisbrick, Julia; Quaglino, Pietro; Zinzani, Pier Luigi; Wolter, Pascal; Sanches, Jose A; Ortiz-Romero, Pablo L; Akilov, Oleg E; Geskin, Larisa; Trotman, Judith; Taylor, Kerry; Dalle, Stephane; Weichenthal, Michael; Walewski, Ja...
Journal:
Lancet
Issue:
Volume 390:Issue 10094(2017)
Page Start:
555
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

40. Case Report: Encephalitis, with Brainstem Involvement, Following Checkpoint Inhibitor Therapy in Metastatic Melanoma. (30th May 2017)

Authors:
Bossart, Simon; Thurneysen, Selina; Rushing, Elisabeth; Frontzek, Karl; Leske, Henning; Mihic‐Probst, Daniela; Nagel, Hannes W.; Mangana, Johanna; Goldinger, Simone M.; Dummer, Reinhard
Journal:
Oncologist
Issue:
Volume 22:Number 6(2017)
Page Start:
749
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗